Oxford Medical Diagnostics (OMD and Michell Instruments (MI) announced a new partnership aimed at pioneering advanced laser absorption spectroscopy applications in industrial gas detection and analysis.
Under the terms of the agreement, the two companies will focus on the targeting, design and pre-commercial development of new industrial gas detection and measurement devices for various industrial purposes, using optical, acoustic, plasma emission and related spectroscopic technologies. OMD will be responsible for the design and the development, in partnership with Michell, who will be focusing on the commercialization. The partners may also involve further third parties in the future.
The new devices will integrate OMD’s proprietary technologies such as Cavity Enhanced Absorption Spectroscopy (CEAS), Broadband Cavity Enhanced Absorption Spectroscopy (BBCEAS) and Plasma Emission Spectroscopy (PES), besides various non-proprietary technologies. The companies expect the first devices to be in the market in 2012.
Key industrial applications will include the detection of water in natural gas and other commercially important gases, as well as the measurement of environmentally damaging pollutants in the oil and gas industry.
“This is another exciting partnership for Oxford Medical Diagnostics, working alongside one of the global leaders in sensory and measurement solutions,” said OMD’s CEO, Tony Marchington. “In addition to bringing us significant revenues as we develop the company, the partnership allows us to expand our existing gas analysis and detection technologies to new markets and new industrial applications, without diverting us from our core mission of delivering breath diagnostic solutions.”
“The co-operation with OMD is a great opportunity for Michell Instruments to further innovate leading gas analysis technologies, enabling us to provide an improved level of service to our customers,” said Mike Bannister, CEO of Michell Instruments.
Financial terms of the agreement were not disclosed.